Prelude Therapeutics Inc (PRLD) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US74065P1012
Prelude Therapeutics Inc financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 12.14 m USD |
| Operating income | -104.57 m USD |
| EBIT | -99.50 m USD |
| Net income | -99.50 m USD |
| Diluted EPS – continuing operations | -1.29 USD |
Full history since 2018, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Prelude Therapeutics Inc
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
More stocks
- Hong Tai Electric Industrial Co Ltd (1612.TW)
- Alpine Income Property Trust, Inc. (PINE)
- InfuSystem Holdings, Inc (INFU)
- Etoiles Capital Group Co., Ltd. Class A Ordinary Shares (EFTY)
- Haibo Heavy Engineering Science and Technology Co Ltd (300517.SZ)
- Eurobio Scientific SA (ALERS.PA)
- Holley Inc. (HLLY)
- 3D SYSTEMS CORP (DDD)
- OVB Holding (O4B.DE)
- FIRST UNITED CORP/MD/ (FUNC)
- Gruvaktiebolaget Viscaria (VISC.ST)
- ASP Isotopes Inc. (ASPI)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.